Validation of prediction of distant recurrence (DR) by Prosigna (PAM50) in subgroups of a Danish Breast Cancer Cooperative Group (DBCG) cohort of node-positive (N1), hormone receptor–positive (HR+), postmenopausal early breast cancer (EBC) patients allocated 5yr of endocrine therapy (ET).

Authors

Bent Ejlertsen

The Danish Breast Cancer Cooperative Group, DBCG Secretariat, Rigshospitalet, Copenhagen, Denmark

Bent Ejlertsen , Maj-Britt Jensen , Jens Ole Eriksen , Torben Kibøll , Birgitte Bruun Rasmussen , Ann S. Knoop , Sean Ferree , Taryn Haffner , Carl Schaper , Anne-Vibeke Lænkholm

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Prediction of late distant recurrence (DR) using the Prosigna (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal women diagnosed with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET).

First Author: Anne-Vibeke Lænkholm

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Prediction of 10yr distant recurrence (DR) using the Prosigna (PAM50) assay in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone.

First Author: Anne-Vibeke Lænkholm

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

A validated model to predict low recurrence risk distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer patients.

First Author: Yasue Tsuchida

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the “SOLE” trial.

First Author: Elena Guerini Rocco